Prevalence of comorbidities in hospitalized populationwith COVID-19: Our experience

Background and Aim: Our objective was to evaluate the prevalenceof comorbidities in our hospitalized population with COVID-19 Materials and Methods: Forty-two patients (64 29% males,25 71% females;mean age of 70 75 ±13 73 yrs), admitted toour Hospital between March and June 2020, had been identifiedas having laboratory-confirmed 2019-SARS-CoV infection Results: On admission 83 33% of patients presented with dyspnea, 80 95% with cough and 78 75% with fever Diarrhea was uncommon (19 05%) Patients were classified according to their BMI(kg/m2) as lean (18 5-25) or affected by grade 1 obesity (25-29 9), grade II obesity (30-34 9) and grade III obesity (= 35) Obesity was present in 50% of cases;grade I 35 71%, gradeII and grade III 11 90% and 2 38%, respectively Hypertension waspresent in 92 86% of patients, COPD in 54 76%, chronic kidneydisease in 45 24%, ischemic heart disease in 35 71%, diabetesin 33,33%, dementia in 30,95% and atrial fibrillation in 7 14% On admission to the hospital lymphocytopenia was a frequent laboratory finding (97 62%) The coagulation profile revealed an elevation of fibrinogen (66 67%) and D-dimer (85 71%) levelsdespite a normal PT and APTT The elevation of the pro BNP levelswas observed in 61 90% and troponin levels were at the sametime elevated in 13 16% of COVID-19 patients Twelve patients(28 5%) died Coronary artery disease was found in 70% of them Conclusions: Comorbidities are common in patients with COVID-19 Although COVID 19 has been initially associated to a respiratory disease, it may involve the cardiovascular system with adramatic impact